Healthcare Industry News: Stereotactic
News Release - January 11, 2011
First Five-Year Outcomes Published on CyberKnife Radiosurgery for Prostate CancerStudy Demonstrates Long-Term Efficacy of Five-Day Course of CyberKnife Prostate Treatment
SUNNYVALE, Calif., Jan. 11, 2011 -- (Healthcare Sales & Marketing Network) -- Accuray Incorporated (Nasdaq:ARAY ), a global leader in the field of radiosurgery, announced today the first published five-year outcomes on low risk prostate cancer patients treated with the CyberKnife® Robotic Radiosurgery System. The multi-center study, published in the January 10, 2011 issue of Radiation Oncology, found that 93 percent of patients had no recurrence of their cancer at a median follow-up of five years, a rate that compares favorably to results obtained with other treatment modalities, including surgery and conventional radiation therapy.
The study, "Stereotactic Body Radiotherapy for Low-Risk Prostate Cancer: Five-Year Outcomes," combined data from 41 patients treated at Stanford University in Stanford, Calif. and Naples Community Hospital in Naples, Fla. with a median follow-up of five years. The paper represents the longest published study to date on the use of CyberKnife radiosurgery, also referred to as Stereotactic body radiotherapy (SBRT), as a treatment approach for clinically localized, low-risk prostate cancer. In addition to demonstrating high five-year disease-free survival rates, the study also found generally low levels of urinary and rectal toxicity following the five-day course of treatment, concluding that CyberKnife radiosurgery can achieve high rates of disease control while sparing critical structures, thereby minimizing undesirable side effects typically associated with prostate cancer treatments and preserving patients' quality of life.
"As a non-invasive treatment option completed in just five visits, Stereotactic radiotherapy with the CyberKnife System offers patients the benefits of more rapid recovery, reduced travel costs and less time off work, allowing them to return to their normal, daily routines almost immediately as compared with the standard nine-week course of radiotherapy," said Christopher King, M.D., an author on the study who is now an Associate Professor of Radiation Oncology and Urology at the UCLA School of Medicine. "In addition, because CyberKnife radiosurgery costs less than conventional radiation and avoids the anesthesia and hospital stay associated with surgery, our national health care system benefits from reduced health care costs."
The past 12 months have seen the publication and presentation of numerous shorter term CyberKnife prostate radiosurgery experiences demonstrating encouraging outcomes. This paper supports these outcomes within a long-term follow-up study. Additional this month, the Accuray sponsored multi-center homogeneous prostate study for low and intermediate risk patients, led by the team at the Swedish Cancer Center in Seattle, accrued the final of 294 patients, providing a broad foundation for future long-term multi-center results.
"The publication of five-year clinical outcomes represents a significant milestone for CyberKnife radiosurgery and is important news for physicians to consider when determining the best course of treatment for prostate cancer patients," said Euan S. Thomson, Ph.D., president and CEO of Accuray. "We look forward to this study and other multi-center studies providing additional long-term quality support of CyberKnife prostate radiosurgery outcomes."
Click here to see a patient education video about how prostate cancer is treated with the CyberKnife System.
About the CyberKnife® Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic radiosurgery system designed to treat tumors anywhere in the body non-invasively. Using continual image guidance technology and computer controlled robotic mobility, the CyberKnife System automatically tracks, detects and corrects for tumor and patient movement in real-time throughout the treatment. This enables the CyberKnife System to deliver high-dose radiation with pinpoint precision, which minimizes damage to surrounding healthy tissue and eliminates the need for invasive head or body stabilization frames.
Accuray Incorporated (Nasdaq:ARAY ), based in Sunnyvale, Calif., is a global leader in the field of radiosurgery dedicated to providing an improved quality of life and a non-surgical treatment option for those diagnosed with cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery System, which extends the benefits of radiosurgery to include extracranial tumors, including those in the spine, lung, prostate, liver and pancreas. To date, the CyberKnife System has been used to treat more than 100,000 patients worldwide and currently more than 215 systems have been installed in leading hospitals in the Americas, Europe and Asia. For more information, please visit www.accuray.com.
Safe Harbor Statement
The foregoing may contain certain forward-looking statements that involve risks and uncertainties, including uncertainties associated with the medical device industry. Except for the historical information contained herein, the matters set forth in this press release, including statements relating to clinical experience and market acceptance are forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements speak only as of the date the statements are made and are based on information available at the time those statements are made and/or management's good faith belief as of that time with respect to future events. You should not put undue reliance on any forward-looking statements. Important factors that could cause actual performance and results to differ materially from the forward-looking statements we make include: range of treatment options, clinical applications, and market acceptance of products and other risks detailed from time to time under the heading "Risk Factors" in our report on Form 10-K for our 2010 fiscal year, our form 10-Q filed on November 8, 2010 and our other filings with the Securities and Exchange Commission.. The Company's actual results of operations may differ significantly from those contemplated by such forward-looking statements as a result of these and other factors. We assume no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.